Health Care & Life Sciences » Pharmaceuticals | Tetraphase Pharmaceuticals Inc.

Tetraphase Pharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
10,486.00
9,098.00
11,686.00
5,145.00
9,666.00
18,904
SG&A Expense
38,547.00
74,740.00
94,491.00
82,693.00
124,950.00
91,479
EBIT
28,190.00
65,766.00
82,998.00
77,830.00
115,715.00
73,281
Non Operating Income/Expense
263.00
24.00
2.00
-
-
-
Interest Expense
1,719.00
1,017.00
231.00
-
-
624
Pretax Income
29,636.00
66,742.00
83,189.00
77,480.00
114,752.00
72,158
Consolidated Net Income
29,636.00
66,742.00
83,189.00
77,480.00
114,752.00
72,158
Net Income
29,636.00
66,742.00
83,189.00
77,480.00
114,752.00
72,158
Net Income After Extraordinaries
29,636.00
66,742.00
83,189.00
77,480.00
114,752.00
72,158
Net Income Available to Common
29,636.00
66,742.00
83,189.00
77,480.00
114,752.00
72,158
EPS (Basic)
1.78
2.49
2.36
2.11
2.63
1.37
Basic Shares Outstanding
16,665.00
26,807.00
35,261.00
36,704.00
43,582.00
52,514
EPS (Diluted)
1.78
2.49
2.36
2.11
2.63
1.37
Diluted Shares Outstanding
16,665.00
26,807.00
35,261.00
36,704.00
43,582.00
52,514
EBITDA
28,061.00
65,642.00
82,805.00
77,548.00
115,284.00
72,705
Non-Operating Interest Income
10.00
17.00
42.00
350.00
963.00
1,747

About Tetraphase Pharmaceuticals

View Profile
Address
480 Arsenal Street
Watertown Massachusetts 02472
United States
Employees -
Website http://www.tphase.com
Updated 07/08/2019
Tetraphase Pharmaceuticals, Inc. engages in the development and production of novel antibiotics for serious and life-threatening bacterial infections. It is currently developing a product candidate, eravacycline, a fully synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Watertown, MA.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.